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Immunotherapy for the treatment of breast cancer can be categorized as either (a) specific stimulation of the
immune system by active immunization, with cancer vaccines, or (b) passive immunization, such as tumor-specific
antibodies (including immune modulators) or adoptive cell therapy that inhibit the function of, or directly kill, tumor
cells. We will present the current information and the future perspectives of immunotherapy in patients with breast
cancer, including the prognostic role of tumor infiltrating lymphocytes, immune signatures, targeted therapies
modulating the immune system, and tumor antigen cancer vaccines. Active immunotherapy in breast cancer and
its implementation into clinical trials have been largely a frustrating experience in the last decades. The concept that
the immune system regulates cancer development is experiencing a new era of interest. It is clear that the cancer
immunosurveillance process indeed exists and potentially acts as an extrinsic tumor suppressor. Also, the immune
system can facilitate tumor progression by sculpting the immunogenic phenotype of tumors as they develop. Can-
cer immunoediting represents a refinement of the cancer immunosurveillance hypothesis and resumes the complex
interaction between tumor and immune system into three phases: elimination, equilibrium, and escape. Major
topics in the field of immunology deserve a response: what do we know about tumor immunogenicity, and how
might we therapeutically improve tumor immunogenicity? How can we modulate response of the immune system?
Is there any gene signature predictive of response to immune modulators? The success of future immunotherapy
strategies will depend on the identification of additional immunogenic antigens that can serve as the best tumor-
rejection targets. Therapeutic success will depend on developing the best antigen delivery systems and on the elu-
cidation of the entire network of immune signaling pathways that regulate immune responses in the tumor micro-
environment.Introduction
Evading immune destruction is an emerging hallmark of
cancer. The immune system plays a dual role in cancer:
it not only can suppress tumor growth by destroying
cancer cells or inhibiting their outgrowth but also pro-
motes tumor progression either by selecting for tumor
cells that are more fit to survive in an immunocompe-
tent host or by establishing conditions within the tumor
microenvironment that facilitate tumor outgrowth. The
conceptual framework called ‘cancer immunoediting’ in-
tegrates the immune system’s dual host-protective and
tumor-promoting roles. Nonetheless, numerous studies
have shown that tumors can be recognized and* Correspondence: giuseppe.curigliano@ieo.it
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2014contained for extended periods of time by the immune
response through the concerted action of the innate and
adaptive immune responses [1]. Despite these efforts,
cancer still develops, at increased frequency with age, as
a consequence of selecting less immunogenic tumor
cells (immunoediting) or the increased effectiveness of
tumor-mediated immunosuppression (immune subver-
sion) or both [2,3]. In Figure 1 are reported major func-
tions and components of the immune system relevant
for potential breast cancer (BC) therapy.
In BC, recent evidence has demonstrated that
immune-related factors play an important role in defin-
ing patient prognosis and their response to treatment.
These include the extent of lymphocyte infiltration in
tumor tissue and a class of gene expression signatures,
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Figure 1 Immune system functions and components relevant to breast cancer therapy. CTLA-4, cytotoxic T lymphocyte-associated antigen
4; MHC, major histocompatibility complex; NK, natural killer; PD-1, programmed death-1; PDL-1, PD-1 ligand 1; TAA, tumor-associated antigen;
TCR, T-cell receptor; Treg, regulatory T.
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subgroups with different sensitivities to standard treat-
ments. Despite these new insights, clinicians still rely
primarily on classic clinical-pathological features such as
tumor size and lymph node involvement for daily patient
management, and it is difficult to see how these parame-
ters may be implemented in the clinic in the future. This
review will highlight the importance of exploring the im-
mune system in both research and clinical settings, since
its role in defining BC behavior is proving to be a signifi-
cant factor.
The role of the lymphocytic infiltrate in breast
cancer
Over the past few decades, a growing body of evidence
has emerged demonstrating that the immune system
participates both in tumor development (via chronic in-
flammation orchestrated by the innate immune system)
and in tumor elimination and control (through the ac-
tions of the adaptive immune system) [4]. The presence
of tumor-infiltrating lymphocytes (TILs) is observed in
some breast tumors and has been reported to be a good
prognosis feature for some forms of the disease [5-7],
particularly for rapidly proliferating tumors correlating
with negative axillary nodal status, smaller tumor size,
and lower grade [6]. Similarly, TIL count has been asso-
ciated with better survival in patients with estrogen re-
ceptor (ER)-negative tumors [8,9]. Also, TILs have been
negatively correlated with patient’s age at diagnosis [8,9].
Recently, TILs have emerged as a potential prognostic
and predictive marker in BC, especially in the triple-
negative (TN) and HER2-positive subtypes. Loi andcolleagues [10] have evaluated the predictive value of
TIL in 935 patients in the FinHER (Finland Herceptin)
trial. Among the 134 TN patients receiving docetaxel
and fluorouracil/epirubicin/cyclophosphamide (FEC) or
vinorelbine and FEC, the 3-year recurrence-free survival
was 90% in the case of extensive lymphocyte infiltrate
(intratumoral or stromal TIL >30%) versus 66% in the
case of non-extensive lymphocyte infiltrate (P = 0.007).
In locally advanced BC treated with neoadjuvant chemo-
therapy, the presence of TILs in the primary biopsy pre-
dicts pathologic complete response [9]. In this study,
TIL was composed of both CD3+ and CD20+ cells. The
same group has recently evaluated the prognostic and
predictive value of TILs in a large cohort of lymph
node-positive early-BC patients prospectively randomly
assigned to receive either high-dose anthracycline-based
chemotherapy or a combinatorial regimen involving
anthracyclines and docetaxel within the BIG02-98 trial
[11]. TILs+ were strongly associated with good prognosis
among patients with TN BC, whereas TILs had no prog-
nostic value among patients with HER2+ BC. However,
TILs+ were associated with improved therapeutic re-
sponses to high-dose anthracyclines in patients with
HER2+ BC [11]. Interestingly, Demaria and colleagues
[12] have reported that taxane-based primary chemo-
therapy converted 7 out of 21 breast tumors from TIL−
to TIL+ and that the post-chemotherapy TIL+ status was
associated with an improved clinical response. Further-
more, Ladoire and colleagues [13] have reported that
neoadjuvant chemotherapy increased the CD8+ infiltra-
tion in the tumor. This post-treatment infiltration is as-
sociated with an improved outcome. It is worthy to
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of chemotherapy is the induction of an anti-tumoral im-
mune response. The group led by Zitvogel [14] has re-
ported that cytotoxic agents, including anthracyclines,
oxaliplatin, and radiation therapy, induce immunogenic
cell death through high-mobility-group box 1 release. In
this model, chemotherapy kills cancer cells. This modal-
ity of cell death itself induces signal danger and tumor-
specific T-cell response. Interestingly, the induction of
T-cell response is highly heterogeneous according to in-
dividuals and tumor characteristics. This inter-individual
variability in the ability of chemotherapy to induce im-
mune response could explain why chemotherapy is not
working the same in all patients. Overall, these findings
provide evidence [13] that TIL assessed at baseline could
stratify patients into a high- or low-risk population.
Moreover, small retrospective hypothesis-generating
studies suggested that post-chemotherapy lymphocyte
infiltration at the tumor bed may be correlated with
prognosis. In conclusion, TIL+ BCs present specific fea-
tures that could have specific clinical implications in
terms of prognosis. These data from population-based
studies or randomized trials will need additional valid-
ation using a prospective trial before implementation. A
potential implication could be to use TILs as inclusion
criteria in large adjuvant trials that include TN BC or
HER2-positive BC. Another potential prognostic impli-
cation relates to the potentially good prognosis of pa-
tients who were TIL− at baseline but became TIL+ after
neoadjuvant therapy [12]. Nevertheless, if these data are
confirmed, they could be used to better stratify which
patients should be included in post-neoadjuvant trials.
Finally, the information that TIL+ is associated with
good outcome is an argument to develop immune strat-
egies in patients with BC. TIL assessment could identify
a subset of TIL− TN and HER2+ BC patients who de-
serve additional therapy. Genomic predictor of chemo-
immunization could represent a new prognostic param-
eter that will allow clinicians to select which TIL− BCs
are candidates for new therapeutics in the (neo)adjuvant
setting, thus decreasing toxicity, decreasing cost,
and making feasible (neo)adjuvant trials. TILs are repre-
sented mainly by non-activated T cells which often be-
come activated after exposure to chemotherapy. More
recently, the nature of TILs has been better character-
ized. Ruffell and colleagues [15] have reported that TILs
are composed mainly of CD3+/CD56− T cells but that a
minority consisted of natural killer (NK) cells or CD20+
cells. The majority of CD3+ cells were either CD4+ or
CD8+ T cells. Interestingly, CD8+ cells did not express
Granzyme B at baseline, which means that they did
present inactivation status, but they did express Gran-
zyme B after neoadjuvant chemotherapy in one third of
the patients. Lastly, a minority of TILs presented T andNK cell features [15]. The genomic characteristics of
TIL+ tumors are important to understand which mo-
lecular mechanisms lead to lymphocyte infiltration. Gen-
omic instability may promote anti-tumor immune
response through tumor-associated antigens. Some
mechanisms of chemokine release by the tumor have
been described and correlated with lymphocyte attrac-
tion. TILs have been associated with CXCL9 and
CXCL13 expression by the tumor [9]. TIL+ tumors
present a specific methylation pattern on immune-
related genes, including CCL5 [16]. A cluster of chemo-
kines is lost in a subset of BC [17].
Immune-related gene signatures
In past years, gene expression profiling has been
used in an effort to more precisely define BC tax-
onomy and identify prognostic and predictive signa-
tures [18]. The common denominator between the
majority of the ‘first generation’ signatures is their
overall capacity to detect subtle differences in the
cell cycle and proliferation. For this reason, they
have not been found to be prognostic in the TN or
HER2+ subtypes since these tumors are by ‘nature’
highly proliferative. Several investigators have tried
to overcome the limitations of these ‘first generation’
signatures by focusing on the BC microenvironment
or immune response (or both) to define promising
‘second generation’ prognostic signatures (Table 1)
[19]. Unsupervised gene expression profiling of
cancer-associated stroma revealed a signature
enriched for CD8+ T-cell responses that was predict-
ive of good prognosis [20]. An immune response
module, the STAT1 module, has been shown to be
associated with survival in patients with TN and
HER2+ [21,22], and in the same BC subtypes, the
overexpression of immune-related genes was able to
identify subgroups of patients with a better progno-
sis [7,23]. Together, these investigations suggest that
immune modulation may be important, particularly
in highly proliferative subtypes such as TN and
HER2+.
Immunogenicity and response to therapies
affecting the immune system
BC has not been traditionally considered immunogenic,
as it does not occur at a higher incidence in the im-
munosuppressed populations who have been treated
with immunosuppressive therapies [27], as opposed to
melanoma and renal cell carcinoma, which have been
traditionally considered more responsive to immuno-
therapies. However, it seems that, despite a weak influ-
ence on primary tumor growth, the immune system is
effective in preventing BC metastases [28-30]. The het-
erogeneous expression of tumor antigens within the
Table 1 Immune signatures and their development
Immune signature Signature development
Immune response (IR) module [23] A subclass of estrogen receptor-negative (ER−) tumors that overexpress IR genes and that have a good
prognosis compared with the rest of ER− breast tumors independently of lymph node status or lympho-
cytic infiltration was identified. Subsequently, an associated module of complement and IR genes that
define prognostic markers was identified and validated in over 240 ER− samples.
STAT1 module [22] On the basis of the literature, genes to act as ‘prototypes’ for different biological processes - ER for ER
signaling, HER2 for HER2 signaling, AURKA for proliferation, CASP3 for apoptosis, VEGF for angiogenesis,
PLAU for tumor invasion/metastasis, and, in this case, STAT1 for immune response - were selected. A
comparison of linear models was then applied to generate modules of genes specifically associated with
each of the prototype genes but not with the other prototypes.
B-cell metagene [7] Gene expression patterns of 200 patients who did not receive systemic treatment and co-regulated
genes related to proliferation, steroid hormone receptor expression, and B-cell and T-cell infiltration were
identified after hierarchical cluster analysis was performed. Metagenes were calculated as a surrogate for
all genes contained within a particular cluster and their expression was correlated to time to metastasis.
The B-cell metagene showed independent prognostic information in carcinoma with high proliferative
activity.
IgG, HCK, MHC-I, MHC-II, LCK, STAT1, and
IFN metagenes [24]
Unsupervised hierarchical clustering of genes in 12 primary invasive breast cancer datasets as well as
combined datasets revealed a large cluster of genes with functions in immune cells. Among this cluster,
clusters that contained a minimum number of elements and a minimal average correlation were
selected, and seven metagenes were derived. Each metagene then was associated with a cell type or
immunological state or both.
HRneg/Tneg signature [25] A cohort of patients with node-negative, adjuvant treatment-naïve hormone receptor-negative (HRneg),
and triple-negative (Tneg) breast cancer has been used to define and validate genes predictive for distant
metastatic relapse. A composite HRneg/Tneg signature index was able to identify cases likely to remain
free of metastatic relapse with high accuracy. Of note, significant positive correlation was observed be-
tween the HRneg/Tneg index and three independent immune-related signatures (STAT1, IFN, and IR), and
network analysis showed that the signature was linked to immune/inflammatory cytokine regulation.
Support Vector Machine (SVM) classifier
[26]
Gene expression data of 2,145 invasive early breast adenocarcinomas were collected and used to test
and validate the predictive performance of an SVM classifier based on a 368-gene expression signature
associated with medullary breast carcinoma (MBC), which displays a basal profile but has good progno-
sis. The SVM model accurately classified all MBC samples in the learning and validation sets and was able
to separate 466 cases of basal breast cancers into two subgroups (subgroup 1 and subgroup 2) contain-
ing, respectively, good- and poor-prognosis tumors. Ontology analysis revealed, among other features,
effective IR in the good-prognosis subgroup.
AURKA, aurora kinase A; CASP3, caspase 3; HCK, hemopoietic cell kinase; IFN, interferon; IgG, immunoglobulin G; LCK, lymphocyte-specific kinase; MHC, major histo-
compatibility complex; PLAU, Urokinase-type plasminogen activator; STAT1, signal transducer and activator of transcription 1; VEGF, vascular endothelial
growth factor.
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antigenic profile during the tumor progression, and the
low levels of the antigen, major histocompatibility com-
plex proteins, and other co-stimulatory proteins neces-
sary to generate a strong immune response can explain
this low immunogenicity. Moreover, the tumor micro-
environment releases immune-suppressive factors that
make the antigen presentation difficult and that have a
negative impact on the immune response [31]. More-
over, by blocking endogenous immune checkpoints that
normally terminate immune responses after antigen acti-
vation, it is possible to evade immune destruction. Be-
sides the example of anti-cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) antibody (ipilimumab)
for the treatment of patients with advanced melanoma
[32-34], programmed death 1 (PD-1) might extend the
spectrum of immunotherapy clinical activity in tumor
types traditionally not considered to be immunogenic,
such as metastatic non-small-cell lung cancer [35].
Nonetheless, it seems that any tumor could be immuno-
genic with appropriate immune activation.On the other hand, activation of the immune system
could mediate the anti-tumor effects of several anti-
cancer drugs. In a neoadjuvant clinical trial (Trial of
Principle (TOP) study) in which patients with ER− BCs
were treated with anthracycline monotherapy, high im-
mune module scores were associated with sensitivity to
anthracyclines [36]. The immune system seems also to
be pivotal in determining the response to monoclonal
antibodies (mAbs) and tyrosine kinase inhibitors, and
some evidence indicates a possible role in the response
to endocrine treatment. The humanized immunoglobu-
lin (IgG1) mAb trastuzumab is commonly used to treat
patients with HER2+ BC with increased response rate
and survival [37,38]. Antibody-dependent cellular cyto-
toxicity (ADCC) has long been implicated as one of the
mechanisms of action for trastuzumab [39,40]. Correla-
tive studies have suggested that patients responding to
mAb treatment had higher in situ infiltration of leuko-
cytes and increased capacity to mediate ADCC activity.
Tumor regressions in vivo due to anti-HER2 mAb ther-
apy also require an effective adaptive anti-tumor
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and levels of CD8 and interferon-gamma have been
shown to correlate with anti-HER2 treatment. Therefore,
complete tumor response after molecular targeted ther-
apies requires a functioning immune system, pointing
the way toward radically new combination therapies
with a targeted and immune approach [41].
In recent years, the better knowledge of BC biology
has provided an opportunity to develop some types of
immunotherapy to overcome the relative non-
immunogenic property of BC and improve immune re-
sponse. Some molecules such as PD-1 and its ligand
PDL-1, CTLA-4, and immune cells such as regulatory T
(Treg) cells are involved in the induction of tolerance to
antigens, and their upregulation is associated with in-
creased risk of developing BC [42]. The mAbs against
antigen tumor target or immune-regulatory molecules,
cell-based therapies including adoptive transfer of
ex vivo-activated T cells and NK cells, or blockade of
Treg cells could be useful to amplify the anti-tumor re-
sponse. Forkhead box P3 (FOXP3)+ Treg cells are crucial
for the induction and maintenance of peripheral toler-
ance to self-antigens. While exerting their function, Treg
cells can also suppress immune responses to tumor anti-
gens, alloantigens, and allergens [5,43]. The prognostic
importance of FOXP3 expression in patients with BC
has been investigated. FOXP3 expression in BC was as-
sociated with worse overall survival probability, and the
risk increased with increasing FOXP3 immunostaining
intensity [44]. FOXP3 was also a strong prognostic fac-
tor for distant metastases-free survival but not for local
recurrence risk. In multivariate analysis, FOXP3 resulted
in an independent prognostic factor, and the hazard ra-
tios of FOXP3 expression and of lymph node positivity
were similar. In the Milan 3 trial, the probability rates of
10-year survival in the node-negative subgroup were
100% for FOXP3-negative and 82% for FOXP3-positive
patients; corresponding rates in the node-positive sub-
group were 82% for FOXP3-negative and 41% for
FOXP3-positive patients. According to these data, Treg
cells may play an important role in BC immunopathol-
ogy because of their potent suppressive activity of both
T-cell activation and effector function. The modulation
of the immune response by Treg cells can enhance im-
mune response and improve patients’ clinical outcome.
An alternative may be targeting the immune checkpoint
molecules. Preclinical models have shown that inhibitory
signals mediated by co-receptors on tumor-specific T
cells impede anti-tumor immunity and suggest that
blockade of such activity may aid host immune-
mediated tumor elimination. Recently, T-cell checkpoint
inhibitors were shown to induce durable tumor regres-
sion and stabilization of disease in patients with ad-
vanced cancer and give new hope for the treatment ofpatients with BC [45]. PD-1 is an inhibitory receptor ex-
pression on activated T and B cells whose activity may
suppress anti-tumor immunity. Phase I data [46] showed
that blocking the PD-1 immune checkpoint with a tar-
geted antibody may be safe and well tolerated with evi-
dence of anti-tumor activity, presumably through
immunogenic mechanisms as PD-1 receptors are not
expressed on non-hematologic malignancies. The com-
binatorial anti-tumor effects of anti-HER2 and anti-PD1
demonstrated in experimental models are important
proof-of-principle experiments that the anti-tumor adap-
tive immunity provoked by anti-HER2 can be capitalized
upon, providing a new model of potential combination
treatment for women receiving trastuzumab.
Another interesting immune molecule is CTLA-4
(CD152), which is similar to PD-1, but its immune-
inhibitory signals are different. CTLA-4 knockout mice
display early lethality, unlike PD-1 knockouts, which
demonstrate late-onset and organ-specific autoimmun-
ity. Anti-CTLA4 mAb treatment has shown robust
tumor responses in phase III trials, but with considerable
adverse events [32]. Still, combining anti-CTLA-4 mAb
with trastuzumab has shown synergy in preclinical
mouse models [47].
Hence, immunotherapeutics that augment CD8 T-cell
anti-tumor activity - such as anti-PD1 and anti-CTLA4
mAbs - given in combination with trastuzumab in pa-
tients with HER2+ BC may improve outcome by involv-
ing and enhancing critical host immunity [41,48,49].
Given this evidence, the evaluation of baseline im-
mune response and the identification of easy-to-define
surrogate markers of immune system activation could be
helpful in the management of BC to identify patients
who may benefit from these combination therapies, even
eliminating the need for combination cytotoxic
chemotherapy.Vaccine-based therapies for breast cancer
Vaccines constitute an active and specific immunother-
apy designed to stimulate the intrinsic anti-tumor im-
mune response by presenting tumor-associated antigens
(TAAs) expressed on normal tissues that are overex-
pressed on tumor cells. Malignant cells can express both
normal self-antigens and specific TAAs that arise from
genetic mutations or epigenetic changes or both, recog-
nized by the immune response through either their loss
or de novo aberrant expression. Many TAAs (including
MUC1, HER-2, CEA, hTER, and WT1) have been identi-
fied and been shown to be specifically recognized by T
cells [50]. Induction of strong immunity by cancer vac-
cines is expected to lead to the establishment of
immunological memory, thereby preventing tumor
recurrence.
Note: This article is part of a series on "Recent advances in
breast cancer treatment and the translational research behind
them", edited by Jenny Chang. Other articles in this series
can be found at http://breast-cancer-research.com/series/
treatment.
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tures affecting immune response in patients with min-
imal tumor burden represents the optimal background
for development of clinical studies in the adjuvant set-
ting as it should allow the immune system to mount a
response before it is overtaken. An active immunization
may provide a non-toxic therapeutic modality able to in-
duce anti-tumor immune responses in patients with can-
cer [51]. However, the majority of the trials so far have
been conducted in the metastatic setting, which could
have significantly impacted the results because of the
large tumor burden [52-56]. Cancer vaccines are more
effective when given in combination with standard can-
cer treatments, which appear to increase their effective-
ness [57-59]. The elimination of Treg cells potentially
provides the basis [55] for the synergistic effect between
cancer vaccines and chemotherapy [58]. To optimize the
immunological response to a vaccination strategy, it is
paramount to identify both the target antigen and the
patient population to be targeted. Large population ana-
lyses on specific BC subtypes are necessary to select pa-
tients who have higher probability to express that
specific antigen. To improve immunotherapy trials, in-
vestigators have to take into account the ability to initi-
ate tumor-specific immunity, either directly by providing
tumor-associated antigens or indirectly by favoring the
cross-presentation of endogenous tumor antigens; the
capacity to recruit effector immune cells within the
tumor site, by increasing tumor visibility; and the ability
to preserve immune cell functionality within the tumor
microenvironment through the subversion of immune-
escape mechanisms. In the adjuvant setting, we can
propose several surrogate markers of activity of a vaccin-
ation strategy. Some are related to immunomonitoring
approaches; some others can be related to detection of
disseminated tumor cells in the bone marrow or circu-
lating tumor cells in the peripheral blood or both
[60,61]. Combined therapies should be proposed to ac-
complish these three features. Furthermore, immuno-
therapy needs a long time before turning into an
efficient anti-tumor response; that is why trials should
ideally target well-defined patients in adjuvant settings
[62].
Conclusions
We have provided an overview of the recent evidence
demonstrating that the immune system plays a critical
role in defining BC prognosis and response to different
treatments. However, more studies are necessary to pre-
cisely define the nature and role of TILs, establish the
clinical value of immune-based prognostic and predict-
ive gene signatures, and optimize standard treatments to
effectively work in tandem with the anti-tumor immune
response. Several questions are raised by all remarkabledata presented in this review; answers to these questions
should be considered possible areas of research in the
following years. Should all patients with cancer be
treated with an active immunotherapy approach or only
individuals potentially more ‘responding’? How can we
predict that the individual will develop an immune re-
sponse against a particular antigen used in the vaccine
formulation? Is there any genetic signature predicting re-
sponse to immunotherapy? What are the risks associated
with such a vaccination (that is, the possibility to de-
velop an autoimmune response)? What is the durability
of immune protection? Can we combine vaccine therapy
with therapeutic mAbs or small target oriented mole-
cules? What is the potential effect of antibodies modu-
lating the immune system in patients with metastatic
BC? Continued basic research into the molecular mech-
anisms regulating carcinogenesis and immunosurveil-
lance/tolerance will identify new potential targets,
introducing vaccine therapy in prevention trials for pa-
tients at high risk for developing cancer. A better under-
standing of the dialogue between cancer and immune
cells could help to improve immunotherapeutic ap-
proaches and foster the development of new drugs that
increase the ability of the immune response to provide
effective and sustained anti-tumor immunity.Abbreviations
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